key: cord-0876275-z7dhi7ec
authors: Kirste, I.; Hortsch, S.; Grunert, V. P.; Legault, H.; Maglinao, M.; Eichenlaub, U.; Kashlan, B.; Pajon, R.; Jochum, S.
title: Quantifying the vaccine-induced humoral immune response to spike-receptor binding domain as a surrogate for neutralization testing following mRNA-1273 (Spikevax) vaccination against COVID-19
date: 2022-03-10
journal: nan
DOI: 10.1101/2022.03.09.22271896
sha: 752e72785342cb0aa7d0708988a436e70f6d4ea4
doc_id: 876275
cord_uid: z7dhi7ec

Background: There is a need for automated, high throughput assays to quantify immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study assessed the combined utility of the Roche assays, Elecsys(R) Anti-SARS-CoV-2 S (ACOV2S) and Elecsys Anti-SARS-CoV-2 (ACOV2N) using samples from the 2019-nCoV vaccine (mRNA-1273, Spikevax) phase 2 trial (NCT04405076). Methods: Samples from 593 healthy participants in two age cohorts (18-54 years and [≥]55 years), who received two injections with either placebo (n=198) or mRNA-1273 at a dose of either 50 [≥]g (n=197) or 100 [≥]g (n=198), were collected at Days 1 (first vaccination), 15, 29 (second vaccination), 43 and 57. ACOV2S results were used to assess the humoral response to vaccination in different clinical trial subgroups and were compared to a live virus microneutralization assay. Sample panels from patients with evidence of previous or concomitant infection (as identified using ACOV2N) or with an inconsistent antibody response pattern were analyzed separately. Results: Receptor-binding domain (RBD)-specific antibodies were readily detectable by ACOV2S for the vast majority of participants (174/189 [50 [≥]g dose group] and 178/192 [100 [≥]g]) at the first time point of assessment, with non-converters predominantly older in age. Complete seroconversion for all participants was observed at the subsequent timepoint (Day 29) and before administration of the second dose of vaccine. Two weeks after the first vaccine dose (Day 15), geometric mean concentration (GMC) of antibody levels were 1.37-fold higher in the 100 [≥]g compared with the 50 [≥]g dose group; this difference reduced to 1.09-fold two weeks after the second dose (Day 43). In both the 50 [≥]g and 100 [≥]g dose groups, a more pronounced response was observed in the younger versus the older age group on Day 15 (2.49-fold and 3.94-fold higher GMC, respectively) and Day 43 (1.35-fold and 1.50-fold higher GMC). Few subjects had a previous or concomitant natural SARS-CoV-2-infection (n=8). Vaccination of pre-infected individuals boosted the immune response to very high ACOV2S results compared to infection-naive vaccine recipients. ACOV2S measurements were strongly correlated with those from the live microneutralization assay (Pearson's r=0.779; p<0.0001) and good qualitative agreement was achieved (100% positive and 91.8% negative percentage agreement; 90.0% positive and 100% negative predictive value). Conclusion: The results from this study confirmed that ACOV2S is a highly valuable assay for the tracking of vaccine-related immune responses. Combined application with ACOV2N enables serologic monitoring for breakthrough infection or stratification of previous natively-infected individuals. The adaptive measuring range and high resolution of ACOV2S allows for the early identification of seroconversion as well as for resolution of very high titers and detection of longitudinal differences between age and dose groups. Additionally, good correlation of ACOV2S with live virus microneutralization indicates the utility of ACOV2S as a reliable estimate of neutralization capacity in routine diagnostic settings.

Background: There is a need for automated, high throughput assays to quantify immune response after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study assessed the combined utility of the Roche assays, Elecsys ® Anti-SARS-CoV-2 S (ACOV2S) and Elecsys Anti-SARS-CoV-2 (ACOV2N) using samples from the 2019-nCoV vaccine (mRNA-1273, Spikevax TM ) phase 2 trial (NCT04405076).

Methods: Samples from 593 healthy participants in two age cohorts (18- . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) measurements were strongly correlated with those from the live microneutralization assay (Pearson's r=0.779; p<0.0001) and good qualitative agreement was achieved (100% positive and 91.8% negative percentage agreement; 90.0% positive and 100% negative predictive value).

The results from this study confirmed that ACOV2S is a highly valuable assay for the tracking of vaccine-related immune responses. Combined application with ACOV2N enables serologic monitoring for breakthrough infection or stratification of previous nativelyinfected individuals. The adaptive measuring range and high resolution of ACOV2S allows for the early identification of seroconversion as well as for resolution of very high titers and detection of longitudinal differences between age and dose groups. Additionally, good correlation of ACOV2S with live virus microneutralization indicates the utility of ACOV2S as a reliable estimate of neutralization capacity in routine diagnostic settings.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that has infected hundreds of millions of people globally since it first emerged in 2019 [1]. To reduce the burden of disease, vaccines have been rapidly developed and administered extensively worldwide [2] . While vaccines can be directed against all viral SARS-CoV-2 proteins, [3, 4] the spike (S) and nucleocapsid (N) proteins are considered the main targets of immune response. To date, the majority of approved vaccines and vaccine candidates are targeted to the S antigen, which facilitates entry to host cells via the angiotensin-converting enzyme 2 (ACE 2) receptor [5] . The immunogenicity and functional importance for host cell entry of the S antigen render it an attractive target for vaccination with strong neutralizing potential. However, strong antigenic drift and immune evasion by the virus was expected and has already occurred in emerging strains of SARS-CoV-2 [6] .

There is growing evidence that the presence of neutralizing antibodies and immunoglobulins can be correlated with protection against SARS-CoV-2 [3, 4, 7, 8] . Although the measurement of neutralizing antibodies by live virus neutralization assays provides a means of direct functional assessment, the requirement for cell culture and live virus preparations renders robust standardization challenging even when applying the same technical setup. As a surrogate for neutralizing titers, the quantification of antibody concentrations using commercially-available immunoassays is an attractive option for measuring the response to vaccination and is supported by observations of a correlation between antibodies targeting the receptor-binding domain (RBD) and virus neutralizing titers in plasma from patients naturally infected with SARS-CoV-2 [9] [10] [11] [12] [13] [14] .

Recent publications have shown that immune response to vaccination is dependent on vaccine type, age, and comorbidities [15] [16] [17] [18] [19] and debates have arisen regarding the need to provide additional doses to vulnerable populations [19, 20] . More recently, the emergence of highly transmissible variants, such as Omicron, has led to a number of countries offering . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2022. ;  booster vaccination doses to the general population [21] , with boosters now known to produce a significant increase in neutralizing activity against the Omicron variant [22] . To further understand the potential benefits of offering additional vaccine doses, there is a high need for sensitive and specific assays that can reliably quantify immune responses to vaccination. In addition, large data sets from well-controlled studies are needed to generate the best possible estimates on antibody response to vaccination.

The Roche Elecsys ® Anti-SARS-CoV-2 S assay (hereby referred to as ACOV2S) is an automated, high throughput assay that quantifies antibodies against the RBD of the S protein, developed to detect low levels of such antibodies with high sensitivity (97.92%) and specificity (99.95%) [23] . In contrast, the Roche Elecsys Anti-SARS-CoV-2 immunoassay (hereby referred to as ACOV2N) specifically identifies antibodies to the N protein and therefore can only detect humoral responses elicited following natural infection and not vaccines targeting the S protein [24] . In a recent analysis of samples from a phase 1 trial of the mRNA-1273 vaccine (Spikevax TM; Moderna, Cambridge, MA), ACOV2S showed absence of any baseline noise indicating high specificity for detecting a vaccine-induced immune response [25] . In addition, moderate to strong correlations were observed between ACOV2S and several neutralization assays.

To generate further evidence of the clinical utility of ACOV2S and ACOV2N, we utilized samples from participants enrolled in a phase 2 trial of the mRNA-1273 vaccine. This study provided a large sample size to confirm previous observations obtained using the phase 1 dataset. In addition, the inclusion of a placebo arm in this study provided additional evidence of the specificity of ACOV2S for the detection of a vaccine-induced immune response.

Furthermore, the study included participants in two age groups (18-54 years and ≥ 55 years), allowing us to determine whether ACOV2S is capable of detecting age-related differences in humoral response. We also compared the results from ACOV2S with results from a live virus neutralization assay used in the phase 2 study. Finally, the combined use of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.09.22271896 doi: medRxiv preprint ACOV2S and ACOV2N provided a method to discriminate between immune responses after vaccination in individuals with or without previous or concomitant SARS-CoV-2 infection.

In this retrospective exploratory analysis, stored samples from participants enrolled in the phase 2 trial of mRNA-1273 (NCT04405076) were included for assessment. Full methodological details of this study, including collection of blood samples, have been described previously [26] . In brief, healthy participants aged 

The ACOV2S assay has been described previously [25] . In brief, samples were quantified for SARS-CoV-2 RBD antibodies with a measuring range of 0.4-25,000 U/mL The assigned U/mL are equivalent to Binding Antibody Units (BAU)/mL as defined by the first World Health Organization (WHO) International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/136). Values that deviated by more than three times the interquartile range (IQR) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ;  from the lower or upper quartile of the assay results were defined as statistical outliers. All outliers were associated with inconsistent patterns of antibody titers, most likely originating from sample mis assignments rather than biological or technical effects.

In addition to the quantification of RBD-specific antibody titers induced by mRNA-1273 vaccination, all samples were assessed on the same cobas e 602 module with the ACOV2N assay [24] . As natural infection with SARS-CoV-2 but not vaccination with mRNA-1273 can trigger a positive ACOV2N result, this assay was used to determine whether participants had been infected naturally with SARS-CoV-2 either before or during the period of investigation.

Neutralizing antibody levels were determined under the phase 2 study protocol [26] and the results were transferred to Roche for analysis. Serum neutralizing antibody titers against SARS-CoV-2 were measured using a live virus microneutralization (MN) assay based on an in situ ELISA readout; further details of this assay can be found in the supplementary appendix of the phase 2 publication [26] . The final reportable value for each sample was the MN 50 titer which refers to the dilution required to achieve 50% neutralization.

In case no significant inhibition of infection was observed (<50% neutralization) with the MN assay, the assay result was qualitatively interpreted as negative for neutralizing activity in all qualitative concordance analyses. In this case, the missing quantitative result was substituted by half the lower limit of quantitation. Samples showing significant inhibition (≥50% neutralization) at any of the applied dilutions were interpreted as positive for neutralizing activity in all qualitative concordance analyses. In case the titer exceeded the measuring range of the MN assay, the quantitative result was substituted by the upper limit of quantitation. Statistical outliers were defined as values that deviated by more than three times the interquartile range (IQR) from the lower or upper quartile of the assay results were defined as statistical outliers. Of note, most MN 50 titers from participants randomized into . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ;  one of the vaccine groups exceeded the assay's measuring range at later visits (Days 43 and 57), so the IQR was severely underestimated and the criterion could not be applied to those visits. A Gaussian distribution fit to the right-censored data with subsequent application of the 3xIQR criterion did not detect any further outliers.

To evaluate the humoral response to vaccination with mRNA-1273, analyses were performed on samples from SARS-CoV-2-naïve participants. Statistical ACOV2S outliers were described separately and were also included in a sensitivity analysis. Confidence in analyzing outliers separately was based on the previously observed reliable performance of ACOV2S [23] and on immunobiological rationale [25] . For the comparison of ACOV2S and the live MN 50 assay, the analysis was performed using samples from SARS-CoV-2-naïve participants, excluding those with either an ACOV2S or MN 50 outlier result. using Passing-Bablok (log-scale) regression analyses [27] with 95% bootstrap CIs were . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [27] ). The software R, version 3.4.0, was used for statistical analysis and visualization [28] .

This analysis included longitudinal sample panels from a total of 593 participants; of these, 295 were aged 18-54 years and 298 were aged is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figures 3 and 4) . Table   1 . Using the 0.8 U/mL ACOV2S cutoff, the PPA and NPV were 100%. The NPA was 91.8%, due to the samples which were already reactive for ACOV2S but did not yet show neutralization in the MN 50 method. The NPA was modestly increased to 93.4% if a higher ACOV2S cutoff of 15 U/mL was used; this higher cutoff has been observed to correlate better with neutralization in samples from participants with a natural infection [29] . although the ability of the GMFRs using the MN 50 method to resolve age-dependent effects is less pronounced than using the ACOV2S method. Of note, the measuring range of the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. A sensitivity analysis that included samples from participants with a natural SARS-CoV-2 infection is shown in Supplementary Figure 5 and demonstrated good concordance between the two assays for these samples.

With a rapidly growing number of SARS-CoV-2 vaccines excelling during clinical development, it is essential to reliably quantify the humoral immune response as a prerequisite to determine its value as a marker of response to vaccination and, ideally, as a surrogate marker of the risk of developing symptomatic disease following infection. In this exploratory analysis of mRNA-1273-vaccinated human samples from a phase 2 trial [26] , results from the ACOV2S assay demonstrated that anti-RBD antibody concentrations increased in a time-, dose-and age-dependent manner.

Vaccination resulted in seroconversion for 100% of participants within four weeks after the first injection with mRNA-1273, and further large increases in antibody titers were measured after the second injection of the same vaccine irrespective of age or dose group (GMFRs from Day 29 to Day 43 were 78 and 64 in the 50 μ g and 100 μ g dose groups, respectively).

Differences in the immune response after application of a 100 μ g vs 50 μ g dose were particularly apparent after the first vaccination compared with the second vaccination and also in the younger vs older age groups. A difference in ACOV2S levels between the two age groups was also observed, with higher seroconversion rate and higher ACOV2S concentrations in the younger age group at Day 15. This is consistent with age-dependent antibody responses reported for other COVID-19 vaccines [30] as well as for vaccines for other infectious diseases [31, 32] . The ACOV2S assay has the capability to track immune responses over time with high resolution, which enables differences due to age, dose groups, and other stratification factors to be studied. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ;  In total, eight participants had a positive ACOV2N result either at baseline or at one of the follow-up visits. Of note, no ACOV2N seroconversion was observed after second injection with mRNA-1273 which is in line with reported vaccine efficacy and protection from infection in this phase [26] . Participants who were vaccinated with mRNA-1273 and had a naturally occurring SARS-CoV-2 infection demonstrated titers exceeding those of naïve recipients. This is consistent with a previous study, which reported that individuals with a prior SARS-CoV-2 infection followed by two doses of an mRNA vaccine had higher S antibody measurements compared with individuals with vaccination alone [33] . Presumably, a significantly sustained immune response and most likely increased protection from infection can be expected for these individuals. Comparative long-term monitoring of pre-infected and SARS-CoV-2-naïve individuals will be required to substantiate these assumptions; however, newly emerging SARS-CoV-2 variants with altered transmissibility and virulence add additional levels of complexity. Together, our results further highlight the use of antibody titer assessment after vaccination especially for older subjects with higher variance in response rate. Stronger seroconversion in individuals with prior infection may alleviate the need for a second dose in those individuals, allowing providers to implement a more targeted and individualized approach to vaccination and balancing protection versus possible side effects.

Good correlation was observed between ACOV2S and the live MN 50 assay. The vast majority of samples with a positive MN 50 result were also positive by the ACOV2S assay resulting in an excellent PPA and NPV. Some disagreement before second vaccination was noted, where some positive ACOV2S results, albeit of relatively low antibody titer, coincided with non-reactive neutralizing antibody test results. This may be due to higher sensitivity of the ACOV2S assay and the higher quantities of RBD antibodies that may be required for significant in vitro neutralization activity [34] . This supports the clinical finding that singledose vaccination does not convey optimal protection from infection and that the reported antibody titers before the second vaccination are not necessarily indicative of immunity. In contrast, the significantly higher RBD antibody titers following two-step vaccination appear . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Overall, these findings are consistent with a previous analysis of ACOV2S values in subjects vaccinated with mRNA-1273 [25] and suggest that ACOV2S-measured antibody levels correlate well with the presence of neutralizing antibodies after vaccination. Combining the high throughput, automated ACOV2S and ACOV2N assays enables stratification of naïve from preinfected individuals and monitoring for concomitant or breakthrough infection.

ACOV2S enables reliable quantification of the humoral immune response to vaccination. Furthermore, the observed high titers are in general indicative of convincing in vitro neutralization capacity and hence are very likely associated with immunity that protects from severe disease. Ongoing research is required to elucidate whether anti-RBD thresholds can be defined that are indicative of prevention of symptomatic infection.

Limitations of our study include the relatively short follow-up, which prevents analysis of the ability of the ACOV2S assay to determine the longevity of antibody response. Further comparison studies using longer-term follow-up are warranted. In addition, the analysis is limited to vaccination with mRNA-1273 and may not be generalizable to all SARS-CoV-2 vaccines.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.09.22271896 doi: medRxiv preprint

Using samples from a large phase 2 study, we confirmed previous results from a phase 1 study and demonstrated that the ACOV2S assay can be used to identify and track vaccinerelated immune responses. Furthermore, the adaptive dynamic range enabled resolution of a wide titer range and differentiation of the humoral immune response in relation to dose and age. Combination with ACOV2N enabled identification of previous or concomitant natural SARS-CoV-2 infection. Good agreement was observed between ACOV2S and the applied live virus neutralization assay, with discrepancies only observed before the second vaccine dose and in patients with low antibody titers. Additional long-term studies will be required to determine whether the ACOV2S assay can be used to identify patients who may remain at risk of symptomatic infection and may require additional booster vaccinations.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.09.22271896 doi: medRxiv preprint

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Viral targets for vaccines against COVID-19

Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity

Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization

Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine

Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls

In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients

Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Omicron variant and booster COVID-19 vaccines

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay

Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2

Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial. medRxiv

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine

Likelihood ratios with confidence: sample size estimation for diagnostic test studies

R: A language and environment for statistical computing. . R Foundation for Statistical Computing 2020

Elecsys® Anti-SARS-Cov-2 s, Instructions for Use

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

Immunosenescence and human vaccine immune responses

Vaccine-induced protection in aging adults and pandemic response

Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection

Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn

We would like to thank the associated mRNA-1273 Study Team for their contribution to data collection as part of the associated Phase II study (NCT04405076). Additionally, we would like to thank Micah Taylor, Kristin Lucas and the lab operators at PPD Central Labs